

168. (New) The therapeutic composition of claims 145-148, wherein the binding agent is present in the composition in an amount of from 1 μ g to 200 μ g per kg of body weight of the host.

169. (New) The therapeutic composition according to any of claims 145-168, wherein the composition further comprises one or more adjuvants, one or more carriers, one or more excipients, one or more stabilizers, one or more imaging reagents, one or more pharmaceutically acceptable carriers and/or physiologically acceptable saline.

REMARKS


With entry of the present Preliminary Amendment, Applicants have deleted claims 1-112, added independent claims 113, 114, 135, 136, and 145-148, and added 48 dependent claims. After entry of this amendment, claims 113-169 are pending. None of these new claims contain new matter, as all of these claims find support throughout the application and claims as originally filed.

The cost for the additional claims has already been paid for as part of the original filing fee of \$2,187.00. Accordingly, applicants believe no additional fees are due. However, the Commissioner is hereby authorized to charge any underpayments or credit any overpayments to our Deposit Account No. 08-0219.

The Examiner is encouraged to call the undersigned at the number listed below to facilitate prosecution.

Respectfully submitted,

HALE AND DORR LLP



Ann-Louise Kerner, Ph.D.

Reg. No. 33,523

Attorney for Applicants

60 State Street
Boston, MA 02109
Tel: (617) 526-6000
Fax: (617) 526-5000

Dated: January 20, 2000

Kerner/altarex/prosecut/prelinandwpd